The argument for using imatinib in CML

由 Claudiani, Simone, Apperley, Jane F.
發表在 Hematology Am Soc Hematol Educ Program (2018)

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations

由 Claudiani, Simone, Apperley, Jane F., Khan, Afzal, Khorashad, Jamshid, Milojkovic, Dragana
發表在 Haematologica (2020)

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

由 Claudiani, Simone, Apperley, Jane F., Gale, Robert Peter, Clark, Richard, Szydlo, Richard, Deplano, Simona, Palanicawandar, Renuka, Khorashad, Jamshid, Foroni, Letizia, Milojkovic, Dragana
發表在 Haematologica (2017)

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia

由 Claudiani, Simone, Gatenby, Aoife, Szydlo, Richard, Nesr, George, Abulafia, Adi Shacham, Palanicawandar, Renuka, Nteliopoulos, Georgios, Khorashad, Jamshid, Foroni, Letizia, Apperley, Jane F., Milojkovic, Dragana
發表在 Haematologica (2019)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

由 Nteliopoulos, Georgios, Bazeos, Alexandra, Claudiani, Simone, Gerrard, Gareth, Curry, Edward, Szydlo, Richard, Alikian, Mary, Foong, Hui En, Nikolakopoulou, Zacharoula, Loaiza, Sandra, Khorashad, Jamshid S., Milojkovic, Dragana, Perrotti, Danilo, Gale, Robert Peter, Foroni, Letizia, Apperley, Jane F.
發表在 Haematologica (2019)